Our lead pipeline product is Dexycu which is being developed as a sustained-released therapy for inflammation associated with cataract surgery. Almost 4 million cataract surgeries are performed annually in the U.S. alone.

This product employs Icon’s Verisome drug delivery platform to dispense a long-acting, biodegradable formulation of the anti-inflammatory agent dexamethasone into the anterior chamber of the eye through a single injection administered immediately following surgery. Dexycu has been specifically designed to deliver a controlled release of the active agent over a sufficient time to provide an alternative to the current standard treatment regimen involving a comparatively burdensome process of patient administered eye drops applied topically several times daily for an extended period of time.

Dexycu has completed phase III and an NDA is planned for 2017.

More information can be found on